Not another PML case…

Biogen Idec announced on Wednesday (Oct. 29, 2008) that another case of progressive multifocal leukoencephalopathy (PML) has been reported in a patient receiving the company’s multiple sclerosis (MS) drug, Tysabri.  This is the sixth overall case of PML reported in patients taking Tysabri and the third since the drug was reintroduced on the market in June 2006.

The news has again affected the commercial outlook of Biogen Idec